

LIBRI IN EXTENSO

Principi di Farmacologia. Le basi fisiopatologiche della terapia. Edizione italiana a cura di: Biggio G, Monti E, Parolaro D, Perletti G.

CEA, Milano, 2006. (American edition: Golan DE, Tashjian AH, Armstrong, EJ, Galanter JM, Armstrong AW, Arnaout RA, Rose HS. Principles of Pharmacology. Lippincott Williams & Wilkins, 2004)

PUBBLICAZIONI SU RIVISTE INTERNAZIONALI

1. Monti E., Paracchini L., Perletti G. (1989). Effect of doxorubicin on calcium receptors of myocardial cells. *Pharmacological Research* 21, 87-89 (IF: 0.701).
2. Perletti G., Monti E., Paracchini L., Piccinini F. (1989). Effect of Trimetazidine on Early and Delayed Doxorubicin Myocardial Toxicity. *Archives internationales de Pharmacodynamie et de Thérapie* 302, 280-289 (IF: 0.582).
3. Bradamante S., Monti E., Paracchini L., Perletti G. (1989). Hypoxia as a risk factor for doxorubicin-induced cardiotoxicity: a NMR evaluation. *Biochemical and Biophysical Research Communications* 163, 682-688 (IF: 3.179).
4. Piccinini F, Monti E, Paracchini L, Perletti G. Are oxygen radicals responsible for the acute cardiotoxicity of doxorubicin? *Adv Exp Med Biol.* 1990;264:349-52.
5. Monti E., Morazzoni F., Perletti G., Piccinini F. (1990). A new approach to the direct detection of free radicals in the intact myocardium. *Free Radical Research Communications* 8, 161-166 (IF: 2.468).
6. Monti E., Paracchini L., Perletti G., Piccinini F. (1991) Protective effects of spintrapping agents on adriamycin-induced cardiotoxicity in isolated rat atria. *Free Radical Research Communications* 14, 4145 (IF: 2.468).
7. Perletti G., Ghessi A., Raffaldoni E., Piccinini F. (1991) The activity of a beta subtype of Protein Kinase C purified from nuclei of human neutrophils is enhanced by treatment with phorbol 12-myristate 13-acetate. *Biochemical and Biophysical Research Communications* 181, 348-352 (IF: 3.179).
8. Monti E., Monzini F., Morazzoni F., Perletti G. (1992) The inhibitory effect of Cu(II) on Protein Kinase C is enhanced by anthracyclines: an ESR study. *Pharmacological Research* 25, 349-350 (IF: 0.701).
9. Jotti A., Paracchini L., Perletti G., Piccinini F. (1992) Cardiotoxicity induced by doxorubicin in vivo: protective activity of the spin trap α -phenyl-tert-butyl nitron. *Pharmacological Research* 26, 143-150 (IF: 0.701).
10. Monti E., Monzini F., Morazzoni F., Perletti G., Piccinini F. (1993) Interaction of Cu(II) and Cu(II)-anthracycline complexes with Protein Kinase C. Spectromagnetic assessment of the inhibitory effect. *Inorganica Chimica Acta* 205, 181-184 (IF: 1.175).
11. Dolfini E., Dasdia T., Perletti G., Romagnoni M., Piccinini F. (1993) Analysis of calcium dependent Protein Kinase C isoenzymes in intrinsically resistant cloned lines of LoVo cells: reversal of resistance by kinase inhibitor 1-(5-isoquinolylsulfonyl) 2-methylpiperazine. *Anticancer Research* 13, 1123-1128 (IF: 0.926).
12. La Porta C., Perletti G., Piccinini F., Comolli R. (1993) Analysis of calcium dependent Protein Kinase C isoforms in the early stages of Diethylnitrosamine-induced rat hepatocarcinogenesis. *Molecular Carcinogenesis* 8,255-263 (IF: 3.184).
13. Perletti G. (1993) Partial purification of Protein kinase C from rat liver. *Journal of Biochemical and Biophysical Methods* 28(3), 195-204 (IF: 0.763).
14. Perletti G., Piccinini F. (1994) Differential phorbol ester growth modulation and protein kinase C isoenzyme expression in rat hepatoma cells vs. non neoplastic rat hepatocytes. *Oncology reports* 1,963-966 (IF: 0.421).
15. Tessitore L., Perletti G., Sesca E., Pani P., Dianzani M.U., Piccinini F. (1994). Protein kinase C isozyme pattern in liver hyperplasia. *Biochemical and Biophysical Research Communications* 205, 208-214 (IF: 3.179).
16. Perletti G., Smeraldi C., Porro D., Piccinini F. (1994) Involvement of the alpha isoenzyme of protein kinase c in the growth inhibition induced by phorbol esters in MH1C1 hepatoma cells. *Biochemical and Biophysical Research Communications* 205,1589-1594 (IF: 3.179).
17. Tessitore L., Perletti G., Sesca E., Pani P., Piccinini F., Dianzani M.U. (1995) Protein kinase C isozymes during liver regeneration. *Biochemical and Biophysical Research Communications* 214,354-360 (IF: 3.179).
18. Perletti G., Folini M., Lin H., Mischak H., Piccinini F., Tashjian Jr, A.H. (1996) Overexpression of Protein Kinase C epsilon is oncogenic in rat colonic epithelial cells. *Oncogene* 12, 847-854 (IF: 7.991).
19. Perletti G., Tessitore L., Sesca E., Pani P., Dianzani M.U., Piccinini F. (1996). ePKC acts like a marker of progressive malignancy in rat liver, but fails to enhance tumorigenesis in rat hepatoma cells in culture. *Biochemical and Biophysical Research Communications* 221,688-691 (IF: 3.179).
20. Perletti G., Monti E. (1996) PKCs: transducers of critical signals in cancer cells (Review). *International Journal of Oncology* 9,171-177 (IF: 1.110).
21. Sesca E., Perletti G., Binasco V., Chiara M., Tessitore L. (1996) Phosphatidylethanolamine N-methyltransferase 2 and CTP-Phosphocoline cytidyltransferase expressions are related with protein kinase C isozymes in developmental liver growth. *Biochemical and Biophysical Research Communications*, 229, 158-162 (IF: 3.179).
22. Perletti G., Concarì P., Brusaferrì S., Marras E., Piccinini F., Tashjian Jr A.H. (1998). Protein Kinase C ϵ is oncogenic in colon epithelial cells by interaction with the RAS signal transduction pathway. *Oncogene* 16, 3345-3348 (IF: 7.991).

23. Perletti G., Marras E., Concarì P., Piccinini F., Tashjian Jr A.H. (1999). Protein Kinase C δ acts as a growth and tumor suppressor in rat colonic epithelial cells. *Oncogene* 18:1251-1256. (I.F.: 7.991).
24. Perletti G., Concarì P., Giardini R., Marras E., Piccinini F., Folkman, J., Chen, L. (2000) Antitumor activity of Endostatin against carcinogen-induced rat mammary tumors. *Cancer res.* 60:1793-1796, 2000 (I.F.: 8.4).
25. De Eguileor M., Grimaldi A., Tettamanti G., Ferrarese R., Congiu T., Protasoni M., Perletti G., Valvassori R., Lanzavecchia G. *Hirudo Medicinalis*: a new model system for testing activators and inhibitors of angiogenesis. *Angiogenesis*, 4: 299-312, 2001.
26. Marras E, Concarì P, Cortellezzi L, Dondi D, De Eguileor M, Perletti G. Involvement of PI3K in PKC ϵ -mediated oncogenic signal in rat colonic epithelial cells. *Int. J Oncol.*, 19:395-399, 2001 (I.F.: 2.53).
27. Gariboldi M, Ravizza R, Marras E, Perletti G, De Simone A, Piccinini F, Monti E. (2001) Resistance of human leukemic cell lines to 1- β -D-arabinofuranosylcytosine: characterization of an experimental model. *Int. J. Oncol.*, 18:1245-1249. (I.F.: 2.53).
28. de Eguileor M., Tettamanti G., Grimaldi A., Congiu T., Ferrarese R., Perletti G., Valvassori R., Cooper E., Lanzavecchia G. (2003). Leeches: immune response, angiogenesis and biomedical applications. *Current Pharmaceutical Design*, 9:133-147 (I.F.: 5.5).
29. Perletti G, Marras E, Dondi D, Grimaldi A, Tettamanti G, Valvassori R, de Eguileor M. Assessment of the biological activity of an improved naked-DNA vector for angiogenesis gene therapy on a novel non-mammalian model. *Int J Mol Med* 11:691-696, 2003 (I.F.: 1.95).
30. Radaelli A, Zanotto C, Perletti G, Elli V, Vicenzi E, Poli G, De Giulì Morghen C. (2003) Comparative analysis of immune responses and cytokine profiles elicited in rabbits by the combined use of recombinant fowlpox viruses, plasmids and virus-like particles in prime-boost vaccination protocols against SHIV. *Vaccine* 21:2052-2064, (I.F.: 3.0).
31. Tettamanti G, Grimaldi A, Ferrarese R, Palazzi M, Perletti G, Valvassori R, Cooper E, Lanzavecchia G, de Eguileor M. Leech responses to tissue transplantation. *Tissue and Cell* 35, 199-212, 2003. (I.F.: 1.0).
32. de Eguileor M, Tettamanti G, Grimaldi A, Perletti G, Congiu T, Rinaldi L, Valvassori R. (2004) *Hirudo Medicinalis*: Avascular Tissues for Clear-Cut Angiogenesis Studies? *Current Pharmaceutical Design* 10, 1979-1988. (I.F.: 5.5).
33. Perletti G, Osti D, Marras E, Tettamanti G, de Eguileor M (2004). Generation of VSV-G pseudotyped lentiviral particles in 293T cells. *J Cell Mol Med* 8, 142-144, 2004 (I.F.:1.694)
34. A Grimaldi, G Tettamanti, L Rinaldi, G Perletti, R Valvassori, M De Eguileor. Role of cathepsin B in leech wound healing. *Invert Surv J* 1:38-46, 2004
35. Perletti G, Marras M, Osti D, Felici L, Zaro S, de Eguileor M. Protein Kinase C δ requires functional p53 for tumor suppression in human colon cancer cells. *Journal of Cellular and Molecular Medicine*, 8, 563-569, 2004 (I.F.: 2.5).
36. Perletti G, Marras E, Dondi D, Osti D, Congiu T, Ferrarese R, de Eguileor M, Tashjian AH p21^{Waf1/Cip1} and p53 are downstream effectors of Protein Kinase C δ in tumor suppression and differentiation in human colon cancer cells. *International Journal of Cancer*, 113, 42-53, 2005 (I.F.: 4.37).
37. Tettamanti G, Grimaldi A, Congiu T, Perletti G, Raspanti M, Valvassori R, de Eguileor M. Collagen reorganization in leech wound healing. *Biology of the Cell*, 97:557-68, 2005 (2.15).
38. Ferrarese R, Brivio M, Congiu T, Falabella P, Grimaldi A, Mastore M, Perletti G, Pennacchio F, Sciacca L, Tettamanti G, Valvassori R, de Eguileor M Early suppression of immune response in *Heliothis virescens* larvae by the endoparasitoid *Toxoneuron nigriceps* *Invert Surv J* 2: 60-68, 2005
39. Grimaldi A, Caccia S, Congiu T, Ferrarese R, Tettamanti G, Rivas-Pena M, Perletti G, Valvassori R, Giordana B, Falabella P, Pennacchio F, de Eguileor M. Structure and function of the extraembryonic membrane persisting around the larvae of the parasitoid *Toxoneuron nigriceps*. *J Insect Physiol.* 2006;52:870-80
40. Perletti G, Terrian, DM. Distinctive cellular roles for novel protein kinase C isoenzymes. *Current pharmaceutical design* 2006; 12:3117-33.
41. Grimaldi A, Tettamanti G, Perletti G, Valvassori R, de Eguileor M. Hematopoietic cell formation in leech wound healing. *Curr Pharm Des* 2006; 12:3033-41.
42. Osti D, Marras E, Ceriani I, Grassini G, Rubino T, Viganò D, Parolaro D, Perletti G. Comparative analysis of molecular strategies attenuating positional effects in lentiviral vectors carrying multiple genes. *J Virol Methods.* 2006;136:93-101
43. Tettamanti G, Malagoli D, Benelli R, Albini A, Grimaldi A, Perletti G, Noonan DM, de Eguileor M, Ottaviani E. Growth factors and chemokines: a comparative functional approach between invertebrates and vertebrates. *Curr Med Chem.* 2006;13:2737-50
44. Magri V, Trinchieri A, Pozzi G, Restelli A, Garlaschi MC, Torresani E, Zirpoli P, Marras E, Perletti G. Efficacy of repeated cycles of combination therapy for the eradication of infecting organisms in chronic bacterial prostatitis. *International Journal of Antimicrobial Agents.* 2007;29:549-556
45. Trinchieri A, Magri V, Cariani L, Bonamore R, Restelli A, Garlaschi MC, Perletti G. Prevalence of sexual dysfunction in men with chronic prostatitis/chronic pelvic pain syndrome. *Arch Ital Urol Androl.* 2007;79:67-70.
46. Magri V, Trinchieri A, Montanari E, Del Nero A, Mangiarotti B, Zirpoli P, de Eguileor M, Marras E, Ceriani I, Vral A, Perletti G. Reduction of PSA values by combination pharmacological therapy in patients with chronic prostatitis: implications for prostate cancer detection. *Arch Ital Urol Androl* 2007;79:84-92.
47. Magri V, Trinchieri A, Ceriani I, Marras E, Perletti G. Eradication of unusual pathogens by combination pharmacological therapy is paralleled by improvement of signs and symptoms of chronic prostatitis syndrome. *Arch Ital Urol Androl.* 2007;79:93-8.

48. Rubino T, Realini N, Castiglioni C, Guidali C, Viganó D, Marras E, Petrosino S, Perletti G, Maccarrone M, Di Marzo V, Parolaro D. Role in Anxiety Behavior of the Endocannabinoid System in the Prefrontal Cortex. *Cereb Cortex*. 2008; 18(6): 1292-301
49. Massi P, Valenti M, Vaccani A, Gasperi V, Perletti G, Marras E, Fezza F, Maccarrone M, Parolaro D. 5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid. *J Neurochem*. 2008 104:1091-100.
50. Willems P, Claes K, Baeyens A, Vandersickel V, Werbrouck J, De Ruyck K, Poppe B, Van den Broecke R, Makar A, Marras E, Perletti G, Thierens H, Vral A. Polymorphisms in nonhomologous end-joining genes associated with breast cancer risk and chromosomal radiosensitivity. *Genes Chromosomes Cancer*. 2008 47:137-48
51. Perletti G, Vral A, Patrosso MC, Marras E, Ceriani I, Willems P, Fasano M, Magri V. Prevention and modulation of aminoglycoside ototoxicity. *Molecular Medicine Reports*, 2008 1:3-13.
52. Wagenlehner FM, Pilatz A, Naber KG, Perletti G, Wagenlehner CM, Weidner W. Anti-infective treatment of bacterial urinary tract infections. *Curr Med Chem*. 2008;15(14):1412-27
53. Magri V, Trinchieri A, Perletti G, Marras E. Activity of *Serenoa repens*, Lycopene and Selenium on Prostatic Disease: Evidences and Hypotheses. *Arch It Urol Androl* 2008;80:65-78
54. Magri V, Perletti G. How does the pre-massage and post-massage 2-glass test compare to the Meares-Stamey 4-glass test in men with chronic prostatitis/chronic pelvic pain syndrome? *J Urol* 2008;180:1571-1572.
55. Perletti G, Wagenlehner FME, Naber KG, Magri V. Enhanced distribution of 4th-generation fluoroquinolones in the prostatic tissue. *Int J Antimicrob Agents* 2009, 33:206-210.
56. Marras E, Willems P, Vandersickel V, Ceriani I, Thierens H, Vral A, Perletti G. Discrepancies between in silico and in vitro data in the functional analysis of a breast cancer-associated polymorphism in the XRCC6/Ku70 gene. *Mol Med Reports* 2008, 1;805-812.
57. Willems P, De Ruyck K, Van den Broecke R, Makar A, Perletti G, Thierens H, Vral A. A polymorphism in the promoter region of Ku70 associated with breast cancer risk and estrogen exposure. *J Cancer Res Clin Oncol* 2009 Sep;135(9):1159-68
58. Willems P, Magri V, Cretnik M, Fasano M, Jakubowska A, Levanat S, Lubinski J, Marras E, Musani V, Thierens H, Vandersickel V, Perletti G, Vral A. Characterization of the 309T>C missense mutation in BRCA1 codon 64. *Int J Oncol* 2009;34:1005-1015
59. Magri V, Wagenlehner FM, Montanari E, Marras E, Orlandi V, Restelli A, Torresani E, Naber KG, Perletti G. Semen analysis in chronic bacterial prostatitis: diagnostic and therapeutic implications. *Asian J Androl*. 2009 Jul;11(4):461-77
60. Magri V, Perletti G. Chronic Prostatitis and correlations with ED. *Urologia* 2008;75:S16-21.
61. Vandersickel V, Mancini M, Marras E, Willems P, Slabbert J, Philippé J, Deschepper E, Thierens H, Perletti G, Vral A. Lentivirus-mediated RNA interference of Ku70 to enhance radiosensitivity of human mammary epithelial cells. *Int J Radiat Biol*. 2010;86:114-24
62. Magri V, Perletti G, Montanari E, Marras E, Chiaffarino, Parazzini F. Chronic prostatitis and erectile dysfunction: results from a cross-sectional study. *Arch It Urol Androl* 2008;80:172-175.
63. Ravizza R, Molteni R, Gariboldi MB, Marras E, Perletti G, Monti E. Effect of HIF-1 modulation on the response of two- and three-dimensional cultures of human colon cancer cells to 5-fluorouracil. *Eur J Cancer* 2009; 45:890-898
64. Magri V, Marras E, Skerk V, Markotić A, Restelli A, Garlaschi MC, Perletti G. Eradication of *Chlamydia trachomatis* Parallels Symptom Regression in Chronic Bacterial Prostatitis Patients Treated with a Fluoroquinolone-Macrolide Combination. *Andrologia*, 2010;42:366-75
65. Magri V., Perletti G., Bartoletti R., Cai T., Emelyanova I., Mehik A., Morgia G., Skerk V., Trinchieri A., Wagenlehner F.M.E., Naber K.G. Critical issues in Chronic Prostatitis. *Arch It Urol Androl* 2010; 82(2):75-82
66. Magri V, Restelli A, Marras E, Perletti G. A severely symptomatic case of anaerobic chronic bacterial prostatitis successfully resolved with moxifloxacin therapy. *Anaerobe* 2010;16:206-209
67. Perletti G, Montanari E, Vral A, Gazzano G, Marras E, Mione S, Magri V. Inflammation, Prostatitis, Proliferative Inflammatory Atrophy: "fertile ground" for prostate cancer development? *Molecular Medicine Reports* 2010;3:3-12
68. Vandersickel V, Mancini M, Slabbert J, Marras E, Thierens H, Perletti G, Vral A. The radiosensitizing effect of Ku70/80 knockdown in MCF10A cells irradiated with X-rays and p(66)+Be(40) neutrons. *Radiat Oncol*. 2010 Apr 27;5:30
69. Wagenlehner FM, Weidner W, Perletti G, Naber KG. Emerging drugs for bacterial urinary tract infections. *Expert Opin Emerg Drugs*. 2010 Sep;15:375-97.
70. Vandersickel V, Depuydt J, Van Bockstaele B, Perletti G, Philippe J, Thierens H, Vral A. Early increase of radiation-induced γ H2AX foci in a human Ku70/80 knockdown cell line characterized by an enhanced radiosensitivity. *J Radiat Res (Tokyo)*. 2010;51(6):633-41
71. Magri V, Wagenlehner F, Perletti G, Schneider S, Marras E, Naber KG, Weidner W. Use of the UPOINT chronic prostatitis/chronic pelvic pain syndrome classification in European patient cohorts: sexual function domain improves correlations. *J Urol*. 2010;184:2339-2345
72. Vral A, Willems P, Claes K, Poppe B, Perletti G, Thierens H. Combined effect of polymorphisms in Rad51 and Xrcc3 on breast cancer risk and chromosomal radiosensitivity. *Molecular Medicine reports*, 2011, 4(5):901-12.
73. Perletti G, Magri V, Wagenlehner FME, Naber, KG. CXA-101 - Cephalosporin antibiotic. *Drugs of the Future* 2010; 35(12): 977-986.
74. Perletti G, Magri V. α -blockers and antibiotics, alone or in combination, improve symptoms in men with chronic prostatitis/chronic pelvic pain syndrome. *Evid Based Med*. 2011 Oct;16(5):143-4

75. Perletti G, Skerk V, Magri V, Markotic A, Mazzoli S, Parnham MJ, Wagenlehner FM, Naber KG. Macrolides for the treatment of chronic bacterial prostatitis: An effective application of their unique pharmacokinetic and pharmacodynamic profile. *Mol Med Report*. 2011;4:1035-44
76. Magri V, Montanari E, Skerk V, Markotic A, Marras E, Restelli A, Naber KG, Perletti G. Fluoroquinolone-macrolide combination therapy for chronic bacterial prostatitis: retrospective analysis of pathogen eradication rates, inflammatory findings and sexual dysfunction. *Asian J Androl*. 2011;13:819-27.
77. Wagenlehner FM, Wullt B, Perletti G. Antimicrobials in urogenital infections. *Int J Antimicrob Agents*. 2011 38S (2011) 3–10
78. Magri V, Marras E, Perletti G. Chronic bacterial prostatitis: enterococcal disease? *Clin Infect Dis*.;53:1306-7
79. Kolumbic Lakos A, Skerk V, Malekovic G, Dujnic Spoljarevic T, Kovacic D, Pasini M, Markotic A, Magri V, Perletti G. A switch therapy protocol with intravenous azithromycin and ciprofloxacin combination for severe, relapsing chronic bacterial prostatitis: a prospective non-comparative pilot study. *J Chemother*. 2011;23:350-3
80. Magri V, Wagenlehner FM, Perletti G. Re: Samplaski et al.: Inclusion of erectile domain to UPOINT phenotype does not improve correlation with symptom severity in men with chronic prostatitis/chronic pelvic pain syndrome. (*Urology* 2011;78:653-658). *Urology*. 2012;79:487-8; author reply 488-9.
81. Vral A, Magri V, Montanari E, Gazzano G, Gourvas V, Marras E, Perletti G. Topographic and quantitative relationship between prostate inflammation, proliferative inflammatory atrophy and low-grade prostate intraepithelial neoplasia: A biopsy study in chronic prostatitis patients. *Int J Oncol*. 2012;41:1950-8
82. Wagenlehner FM, van Till JW, Magri V, Perletti G, Houbiers JG, Weidner W, Nickel JC. National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) Symptom Evaluation in Multinational Cohorts of Patients with Chronic Prostatitis/Chronic Pelvic Pain Syndrome. *Eur Urol*. 2013;63:953-9
83. Magri V, Wagenlehner FM, Marras E, VAN Till JW, Houbiers J, Panagopoulos P, Petrikkos GL, Perletti G. Influence of infection on the distribution patterns of NIH-Chronic Prostatitis Symptom Index scores in patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). *Exp Ther Med*. 2013;6:503-508
84. Wagenlehner FM, Fröhlich O, Bschleipfer T, Weidner W, Perletti G. The Integral Theory System Questionnaire: an anatomically directed questionnaire to determine pelvic floor dysfunctions in women. *World J Urol*. 2014, 32:769-781
85. Parnham MJ, Haber VE, Giamarellos-Bourboulis EJ, Perletti G, Verleden GM, Vos R. Azithromycin: Mechanisms of action and their relevance for clinical applications. *Pharmacol Ther*. 2014 143:225-245
86. De Lerma Barbaro A, Perletti G, Bonapace IM, Monti E. Inflammatory cues acting on the adult intestinal stem cells and the early onset of cancer. *Int J Oncol*. 2014; 45:959-968
87. Cai T, Pisano F, Magri V, Verze P, Mondaini N, D'Elia C, Malossini G, Mazzoli S, Perletti G, Gontero P, Mirone V, Bartoletti R. Chlamydia trachomatis Infection Is Related to Premature Ejaculation in Chronic Prostatitis Patients: Results from a Cross-Sectional Study. *J Sex Med*. 2014;11:3085-92
88. Magri V, Marras E, Restelli A, Wagenlehner FM, Perletti G. Multimodal therapy for category III chronic prostatitis/chronic pelvic pain syndrome in UPOINTS phenotyped patients. *Exp Ther Med*. 2015 Mar;9(3):658-666
89. Bartoletti R, Cai T, Perletti G, M E Wagenlehner F, Bjerklund Johansen TE. Finafloxacin for the treatment of urinary tract infections. *Expert Opin Investig Drugs*. 2015;24(7):957-63
90. Perletti G, Monti E, Marras E, Cleves A, Magri V, Trinchieri A, Rennie PS. Efficacy and safety of second-line agents for treatment of metastatic castration-resistant prostate cancer progressing after docetaxel. A systematic review and meta-analysis. *Arch Ital Urol Androl*. 2015 Jul 7;87(2):121-9

REVIEW SISTEMATICHE E META-ANALISI - COCHRANE LIBRARY (Impact Factor 2013: 5.9)

91. Perletti G, Marras E, Wagenlehner FM, Magri V. Antimicrobial therapy for chronic bacterial prostatitis. *Cochrane Database Syst Rev*. 2013 Aug 12;8:CD009071

PUBBLICAZIONI SU RIVISTE NAZIONALI

1. Marras E, Concarì P, Badaloni A, Perletti G. (1999) Gli inibitori dell'angiogenesi: un nuovo approccio alla terapia dei tumori? *Geriatric & Medical Intelligence*, 8:9-17.
2. Perletti G., Marazzi M., Pozzi G., Falcone L., Marras E., Baruffi S., Scida G., Gualandri L., Ubbiali A. e Cova D. (2000) Terapia genica: una sfida per la medicina del nuovo millennio. *Geriatric & Medical Intelligence*, 9:7-17.
3. Magri V, Trinchieri A, Perletti G, Restelli A, Garlaschi MC, Torresani E. Infezioni urogenitali a eziologia batterica: diagnosi dell'infertilità su base infettiva. *Microbiologia medica* 21, 141-143, 2006.

CAPITOLI DI LIBRI:

1. Piccinini F., Monti E., Paracchini L. and Perletti G. Are oxygen radicals responsible for the acute cardiotoxicity of doxorubicin? In: *Antioxidants in Therapy and Preventive Medicine*, pp. 349-352. 1990, Editors: Ingrid Emerit, Lester Packer, Christian Auclair; Plenum Press, New York.
2. De Eguileor M, Tettamanti G, Grimaldi A, Ferrarese R, Perletti G, Valvassori R, Cooper E, Lanzavecchia G. Leech immune responses: contributions and biomedical applications. A new model for analyzing antimicrobial peptides with biomedical applications. E.L. Cooper, Editor. *NATO Science Series*, IOS press, 2002

3. Cova D, Perletti G, Processi di angiogenesi. In: Nuovi Farmaci biomolecolari in Oncologia Medica. Un manuale per il clinico, Vol. I. Editors: Vito Lo russo, Saverio Cinieri, Dario Cova, Nicola Silvestris. Editore Ragusa, Bari, 2005
4. Wagenlehner FME, Wullt B, Perletti G. Antimicrobials in urogenital infections. Chapter: Aetiology, antimicrobial resistance of uropathogens, antibiotic therapy and policy. In: Urogenital Infections – 2010 edition, Naber, Schaeffer, Heyns, Matsumoto, Shoskes, Bjerklund-Johansen (eds). European Association of Urology – International Consultation on Urological Diseases. Pp.111-127.

COMUNICAZIONI A CONGRESSI PUBBLICATE SU RIVISTE INTERNAZIONALI (dal 2002)

1. Perletti G, Dondi D, de Eguileor M, Osti D and Marras E. Tumor suppressor activity of the delta isoform of protein kinase C. 7th World Congress on Advances in Oncology and 5th International Symposium on Molecular Medicine, 2002. Published in: International Journal of Molecular Medicine, 10, S76 (2002)
2. De Eguileor M, Congiu T, Grimaldi A, Perletti G, Raspanti M, Tettamanti G and Valvassori R. Tumor angiogenesis activators and inhibitors studied in leeches as a new animal model. 7th World Congress on Advances in Oncology and 5th International Symposium on Molecular Medicine 2002. Published in: International Journal of Molecular Medicine, 10, S79 (2002)
3. Perletti G, Marras E, Osti D, Grimaldi A, Ferrarese R, De Eguileor M. Mechanism of action of the tumor suppressor protein kinase C δ . 8th World Congress on Advances in Oncology and 6th International Symposium on Molecular Medicine 2003 Hersonissos. Published in: International Journal of Molecular Medicine, 12, S15 (2003)
4. De Eguileor M, Congiu T, Grimaldi A, Perletti G, Raspanti M, Tettamanti G and Valvassori R. Role of collagen in modulation of angiogenesis and wound repair in non-mammalian model. 8th World Congress on Advances in Oncology and 6th International Symposium on Molecular Medicine 2003. Published in: International Journal of Molecular Medicine, 12, S55 (2003)
5. Perletti G, Marras E, Osti D, Felici L, Zaro S, De Eguileor M. p53 is a key effector of tumor suppressor PKC δ in human colon cancer cells. 9th World Congress on Advances in Oncology and 7th International Symposium on Molecular Medicine 2004. Published in: International Journal of Molecular Medicine, 14, S13, (2004)
6. Grimaldi A, Tettamanti G, Perletti G, Congiu T, Valvassori R, De Eguileor M. Hemopoietic and endothelial cells in leech vasculo-angiogenesis. 9th World Congress on Advances in Oncology and 7th International Symposium on Molecular Medicine 2004. Published in: International Journal of Molecular Medicine, 14, S56, (2004)
7. Osti D, Marras E, Grassini G, Ceriani I and Perletti G. Overcoming position effects: a comparative analysis of lentiviral vectors carrying multiple genes. 10th World Congress on Advances in Oncology and 8th International Symposium on Molecular Medicine. Heraklion, 2005. Published in: International Journal of Molecular Medicine, 16, S24, (2005).
8. Willems P, Claes K, Baeyens A, De Ruyck K, Van Den Broecke R, Makar A, Perletti G, Thierens H and Vral A. Polymorphisms in non homologous end-joining genes associated with breast cancer risk and chromosomal radiosensitivity. 11th World Congress on Advances in Oncology and 9th International Symposium on Molecular Medicine. Heraklion, 2006. Published in: International Journal of Molecular Medicine, 18, S354, (2006).
9. Magri V, Trinchieri A, de Eguileor M, Marras E, Vral A, Perletti G. Combination pharmacological therapy lowers serum prostate-specific antigen in patients with chronic prostatitis: Implications for prostate cancer screening. 12th World Congress on Advances in Oncology and 10th International Symposium on Molecular Medicine. Heraklion, 2007. Published in: International Journal of Molecular Medicine, 20, S126, (2007).
10. Willems P, Claes K, van den Broecke R, Makar A, Ceriani I, Perletti G, Thierens H, Vral A. Association between single nucleotide polymorphisms (SNP) in DNA double strand break repair genes and breast cancer. 12th World Congress on Advances in Oncology and 10th International Symposium on Molecular Medicine. Heraklion, 2007. Published in: International Journal of Molecular Medicine, 20, S125, (2007).
11. Willems P, Levanat S, Magri V, Jakubowska A, Vandersickel V, Musani V, Cretnik M, Marras E, Perletti G, Vral A. Molecular and genetic characterization of the T309C missense transversion in BRCA1 codon 64 (C64R). 13th World Congress on Advances in Oncology and 11th International Symposium on Molecular Medicine. Heraklion, 2008. Published in: International Journal of Molecular Medicine, 22, S23, (2008).
12. Vandersickel V, Marras E, Mancini M, Thierens H, Perletti G, Vral A. Lentivirus-mediated RNA interference of Ku70 to enhance radiosensitivity of human mammary epithelial cells: Implications for breast cancer onset. 13th World Congress on Advances in Oncology and 11th International Symposium on Molecular Medicine. Heraklion, 2008. Published in: International Journal of Molecular Medicine, 22, S23, (2008).
13. Perletti G, Ferrari M, Cosentino M, Marras E, Magri V. The Pharmacogenetics of Aminoglycoside-induced Ototoxicity. 14th World Congress on Advances in Oncology and 12th International Symposium on Molecular Medicine. Loutraki (Athens), 2009. Published in: International Journal of Molecular Medicine, 24, S48, (2009).
14. Vandersickel V, Mancini M, Slabbert JP, Marras E, Thierens H, Perletti G, Vral A. The radiosensitizing effect of Ku70-80 knockdown by RNA interference in the MCF10A breast epithelial cell line irradiated with low-LET X-rays and high-LET radiotherapy neutrons. 14th World Congress on Advances in Oncology and 12th International Symposium on Molecular Medicine. Loutraki (Athens), 2009. Published in: International Journal of Molecular Medicine, 24, S48, (2009).
15. Wagenlehner F, Magri V, Perletti G, Schneider S, Weidner W. Clinical phenotyping of patients with Chronic Prostatitis/Chronic Pelvic Pain Syndrome in two specialized European institutions. American Urological Association Annual Meeting 2010. San Francisco, USA, 29 May-3 June 2010. Published in: J Urol 2010;183:S799.

16. Wagenlehner, F.M.E., Magri, V., Perletti, G., Schneider, S.O., Weidner, W. Evaluation of patients with chronic prostatitis-chronic pelvic pain syndrome by clinical phenotyping in two specialized European institutions. 25th Anniversary EAU Congress, Barcelona, 16-20 April 2010. Published in: *Eur Urol Suppl* 2010;9(2):138
17. Magri, V, Marras, E, Restelli, Garlaschi, Perletti G. Role of *C. trachomatis* and *U. urealyticum* in the Pathogenesis of Chronic Bacterial Prostatitis. 1st Croatian Congress on urogenital and sexually transmitted infections, with international participation. Opatija, 5-7 June 2009
18. Magri V, Wagenlehner F, Schneider S, Marras E, Naber KG, Weidner W, Perletti G. Sexual dysfunction: a critical component of the new UPOINT Chronic Prostatitis/Chronic Pelvic Pain Syndrome phenotyping system. 2nd Croatian Congress on urogenital and sexually transmitted infections, with international participation. Opatija, 14-16 May 2010.
19. Perletti G, Vral A, Montanari E, Gazzano G, Marras E, Magri V. Involvement of inflammation and Proliferative Inflammatory Atrophy in prostate cancer development. 15th World Congress on Advances in Oncology and 13th International Symposium on Molecular Medicine. Loutraki (Athens), 2010. Published in: *International Journal of Molecular Medicine*, 26, S20 (2010).
20. Clinical phenotyping of patients with chronic prostatitis-chronic pelvic pain syndrome in two specialized European institutions Wagenlehner F. Magri V. Perletti G. Schneider S. Weidner W. *Journal of Urology* (2010) 183:4 SUPPL. 1 (e312). Date of Publication: April 2010
21. Prostatic calcifications and symptoms of chronic prostatitis/chronic pelvic pain syndrome Trinchieri A. Perletti G. Magri V. *European Urology, Supplements* (2010) 9:2 (137-138). Date of Publication: April 2010
22. Evaluation of patients with chronic prostatitis-chronic pelvic pain syndrome by clinical phenotyping in two specialized european institutions Wagenlehner F.M.E. Magri V. Perletti G. Schneider S.O. Weidner W. *European Urology, Supplements* (2010) 9:2 (138). Date of Publication: April 2010
23. V. Skerk*, G. Malekovic, A. Kolumbic Lakos, T. Dujnic Spoljarevic, D. Kovacic, M. Pasini, A. Markotic, V. Magri, G. Perletti (Zagreb, HR; Milano, Busto A./Varese, IT) Azithromycin and ciprofloxacin combination therapy in the treatment of chronic bacterial prostatitis caused by traditional pathogens ECCMID 2011.
24. Magri V, Wagenlehner F, Schneider S, Marras E, Naber KG, Weidner W, Perletti G. Sexual dysfunction: a critical component of the new UPOINT Chronic Prostatitis/Chronic Pelvic Pain Syndrome phenotyping system. 2nd Croatian Congress on urogenital and sexually transmitted infections, with international participation. Opatija, 14-16 May 2010.
25. Magri V, Montanari E, Škerk V, Markotić A, Marras E, Naber KG, Perletti G. Fluoroquinolone-Macrolide Combination Therapy in Chronic Bacterial Prostatitis: Effect on Pathogen Eradication Rates, Inflammatory Findings and Sexual Dysfunction. 3rd Croatian Congress on urogenital and sexually transmitted infections, with international participation. Opatija, 20-22 May 2011.
26. Skerk V, Malekovic G, Kolumbic Lakos A, Dujnic Spoljarevic T, Kovacic D, Pasini M, Markotic AQ, Magri V, Perletti G. Azithromycin and Ciprofloxacin combination therapy in the treatment of chronic bacterial prostatitis caused by traditional pathogens. 3rd Croatian Congress on urogenital and sexually transmitted infections, with international participation. Opatija, 20-22 May 2011.
27. Perletti G, Montanari E, Vral A, Marras E, Naber KG, Magri V. Aggressive therapy for chronic prostatitis: Effect on PSA values, inflammatory findings, uropathogen eradication and clinical symptoms. Implications for prostate cancer detection and prevention. 16th World Congress on Advances in Oncology and 14th International Symposium on Molecular Medicine. Rhodes, 2011. Published in: *International Journal of Molecular Medicine*, 28, S33, 2011.
28. Perletti G, Vral A, Montanari E, Gazzano G, Gourvas V, Magri V. Prostatitis, Proliferative inflammatory atrophy and low-grade Prostate Intraepithelial Neoplasia. 4th Croatian Congress on urogenital and sexually transmitted infections, with international participation. Opatija, 11-13 May 2012.
29. Wagenlehner FME, van Till JWQ, Magri V, Perletti G, Houbiers JGA, Weidner W, Nickel JC. National Institute of Health Chronic Prostatitis Symptom Index (CPSI) symptom evaluation in patients with chronic prostatitis / chronic pelvic pain syndrome – A multinational database of 1,563 patients. American Urological Association annual meeting, 2012 may 19-23, Atlanta, GA, USA.
30. Magri V, Trinchieri A, Montanari E, Marras E, Perletti G. Prevalence of erectile and ejaculatory dysfunction in men with chronic prostatitis/chronic pelvic pain syndrome. 26th EAU Congress, Paris, 24-28 February 2012. Published in: *Eur Urol Suppl* 11(1): e44.
31. Perletti G, Magri V, Montanari E, Gazzano G, Gourvas V, Vral A. Relationship between prostatic inflammation, proliferative inflammatory atrophy and prostate intraepithelial neoplasia: a biopsy study. 17th World Congress on Advances in Oncology and 15th International Symposium on Molecular Medicine. Heraklion, 2012. Published in: *International Journal of Molecular Medicine*, 30, S33, 2012
32. Perletti G, Magri V, Marras E, Monti E, Rennie PS, Trinchieri A, Neuberger MM, Dahm P. Emerging second-line therapies for advanced, androgen deprivation-refractory prostate cancer in the post-docetaxel setting. 18th World Congress on Advances in Oncology and 16th International Symposium on Molecular Medicine. Heraklion, 2013. Published in: *International Journal of Molecular Medicine*, S51:286, 2013
33. National institute of health chronic prostatitis symptom index (CPSI) symptom evaluation in patients with chronic prostatitis / chronic pelvic pain syndrome - A multinational study in 1,563 patients Wagenlehner F. Van Till O. Magri V. Perletti G. Houbiers J. Weidner W. Nickel C. *Journal of Urology* (2012) 187:4 SUPPL. 1 (e439). Date of Publication: April 2012
34. Prevalence of erectile and ejaculatory dysfunction in men with chronic prostatitis/chronic pelvic pain syndrome Magri V. Trinchieri A. Montanari E. Marras E. Perletti G. *European Urology, Supplements* (2012) 11:1 (e44-e44a). Date of Publication: February 2012

35. Risk factors analysis in patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) from Finland, Germany, Italy and Switzerland: Results of a multinational observational study. Wagenlehner F.M.E. Spangenberg M. Magri V. Mehik A. Hochreiter W. Bödecker H. Weidner W. Perletti G. *European Urology, Supplements* (2013) 12:1 (e160). Date of Publication: March 2013
36. De Visschere P, Vral A, Perletti G, Pattyn E, Praet M, Magri M, Villeirs G. mpMRI-Histopathologic Correlation of Normal, Benign and Malignant Conditions of the Prostate. ESUR (European Society of Urogenital Radiology) Copenhagen 16-19/09/2015 (SOLO ABSTRACT BOOK)
37. De Visschere P, Vral A, Perletti G, Pattyn E, Praet M, Magri M, Villeirs G. mpMRI-Histopathologic Correlation of Normal, Benign and Malignant Conditions of the Prostate. 4th EAU Section of Urological Imaging (ESUI) meeting in conjunction with the 7th EMUC meeting (European Multidisciplinary Meeting on Urological Cancers). Barcelona, 12/11/2015 (SOLO ABSTRACT BOOK)
38. Perletti G, Monti E, Vral A, Cleves A, Magri V, Trinchieri A, Rennie PS. Efficacy and safety of second-line agents for treatment of metastatic castration-resistant prostate cancer progressing after docetaxel. Systematic review and meta-analysis. 20th World Congress on Advances in Oncology and 18th International Symposium on Molecular Medicine. Athens, 2015. Published in: *International Journal of Molecular Medicine*, S53, 2015